IronEdge: Dual-Use Evaluation of a Novel Iron Protein
| Reference number | |
| Coordinator | IRONIC AB |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | November 2025 - September 2026 |
| Status | Completed |
| Venture | Civil-military synergies |
| Call | Acceleration of civil-military innovations by 2025 |
Important results from the project
The project reached its main goals and TRL 6. Fermentation was scaled to 200 L, yield rose by about 350 percent, and scale-up to 1,000 L with Corden Biochem is under way. In-silico analysis classed the protein as a probable non-allergen. Powder prototypes for military use were produced with preliminary stability data. The regulatory data package for US GRAS and EU Novel Food was defined; filing is planned from 2027. Defense dialogue showed demand for finished, certified products.
Expected long term effects
The project prepares a Swedish-developed iron protein for commercial launch as a certified ingredient, first in the US and then in the EU. For defense, it offers a shelf-stable oral iron source that can be used in rations or as a supplement without cold chain. In the long term, the results can reduce iron deficiency among soldiers and civilians, especially women, and support physical and cognitive performance, recovery and readiness.
Approach and implementation
The project had four work packages: production scale-up, in-silico safety assessment, military formulation and stability, and dual-use regulatory strategy, combined with the LEAD civil-military accelerator. The activities were right and most deliverables were met on time. Dossier filing follows in 2027, as FDA requires data from 1,000 L production. Dialogue with defense stakeholders shifted our focus toward civilian certification as the route into defense. Partner collaboration worked well.